Literature DB >> 11342332

Matrix metalloproteinases and their tissue inhibitors - expression, role and regulation in human malignant non-Hodgkin's lymphomas.

A E Kossakowska1, S J Urbanski, A Janowska-Wieczorek.   

Abstract

Human malignant non-Hodgkin's lymphomas (NHL) represent a heterogeneous group of neoplasms, which vary in their clinical behavior and pathophysiology. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) have been shown to play a role in the pathophysiology and clinical aggressiveness of human NHL. In this setting, MMP-9 and TIMP-1 appear to be the most important members of the MMP and TIMP families, and overexpression of both correlates with a poor clinical outcome of patients with NHL. MMP-9 and TIMP-1, however, act through different mechanisms and are produced by different cell types. Expression of both is upregulated by interleukin-6 (IL-6), a cytokine that is known as one of the factors involved in the pathophysiology of human NHL. In this review we summarize the complex regulation of MMP and TIMP expression in human NHL and propose a mechanism by which MMP-9, TIMP-1 and IL-6 may influence the biology of these tumors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11342332     DOI: 10.3109/10428190009113379

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  8 in total

1.  Relationship between eukaryotic translation initiation factor 4E and malignant angiogenesis in non-Hodgkin lymphoma.

Authors:  Yanxia Zhao; Wenli Liu; Sheng Zhou; Jianfeng Zhou; Hanying Sun
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 2.  Tissue inhibitor of metalloproteinase (TIMP)-1: the TIMPed balance of matrix metalloproteinases in the central nervous system.

Authors:  Jessica Gardner; Anuja Ghorpade
Journal:  J Neurosci Res       Date:  2003-12-15       Impact factor: 4.164

3.  Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Raymond Lai; George Z Rassidakis; L Jeffrey Medeiros; Latha Ramdas; Andre H Goy; Cathy Cutler; Yasushi Fujio; Keita Kunisada; Hesham M Amin; Frederic Gilles
Journal:  Am J Pathol       Date:  2004-06       Impact factor: 4.307

4.  Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues.

Authors:  A C P Riddick; C J Shukla; C J Pennington; R Bass; R K Nuttall; A Hogan; K K Sethia; V Ellis; A T Collins; N J Maitland; R Y Ball; D R Edwards
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

5.  Neutrophil Gelatinase-Associated Lipocalin (NGAL), Pro-Matrix Metalloproteinase-9 (pro-MMP-9) and Their Complex Pro-MMP-9/NGAL in Leukaemias.

Authors:  Sandrine Bouchet; Brigitte Bauvois
Journal:  Cancers (Basel)       Date:  2014-04-04       Impact factor: 6.639

6.  The role of vascular endothelial growth factor and matrix metalloproteinases in canine lymphoma: in vivo and in vitro study.

Authors:  Arianna Aricò; Mery Giantin; Maria Elena Gelain; Fulvio Riondato; Stefano Comazzi; Barbara C Rütgen; Sabine E Essler; Mauro Dacasto; Massimo Castagnaro; Luca Aresu
Journal:  BMC Vet Res       Date:  2013-05-03       Impact factor: 2.741

7.  The pattern of cytokine gene expression in human colorectal carcinoma.

Authors:  Anna Csiszár; Tamás Szentes; Bea Haraszti; Annamária Balázs; Gyôzô G Petrányi; Eva Pócsik
Journal:  Pathol Oncol Res       Date:  2004-06-09       Impact factor: 2.874

8.  B-cell clonogenic activity of HIV-1 p17 variants is driven by PAR1-mediated EGF transactivation.

Authors:  Cinzia Giagulli; Francesca Caccuri; Simone Zorzan; Antonella Bugatti; Alberto Zani; Federica Filippini; Ekta Manocha; Pasqualina D'Ursi; Alessandro Orro; Riccardo Dolcetti; Arnaldo Caruso
Journal:  Cancer Gene Ther       Date:  2020-10-22       Impact factor: 5.987

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.